Central Sleep Apnea from Medications When Drug Cessation or Switching Has Not Reversed CSA

This protocol addresses central sleep apnea (CSA) caused by medication or substance use in patients where the first-line strategy — modifying or stopping the offending agent — has failed to resolve the disorder.

Clinical scenario

Central sleep apnoea arising from the use of an offending medication, including opioids, baclofen, gabapentinoids, or ticagrelor. Medication-induced CSA is sometimes misclassified as primary CSA; correctly identifying its drug-related cause is a critical first step in management.

Previous line — reason for escalation

The initial approach involves cessation or dose reduction of the offending drug and, where possible, switching to an alternative agent — such as an alternative anti-platelet or anti-epileptic drug, changing to buprenorphine/naltrexone in methadone-treated patients, or using theophylline for ticagrelor-induced CSA.

This protocol is indicated when that strategy has not achieved its goal: reversal of central sleep apnoea.

Next-line approach

When drug modification has not resolved the disorder, a device-based ventilation approach is employed. The complete structured regimen — including device selection criteria, clinical decision points, and sequencing — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1183/20734735.0235-2023

Recognition of medication-induced CSA, which is sometimes misclassified as primary CSA, is an important first step in its management, as withdrawal of the offending medication will reverse the disorder.

When this is not possible, treatment with ASV devices has shown success in case studies.

View source ↗